News | Endovascular Aortic Repair | November 11, 2019

Nexus Arch Branch Stent Graft System Shows Positive Mid-term Results

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 


November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. Two-year results from a prospective multicenter premarket study including 25 patients (mean age, 73 years) treated with Nexus were presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

Mid-term results at a mean 25-month follow-up are stable without any material failure or stent graft issues, said presenter Daniel Clair, M.D., chair of the Department of Surgery at Palmetto Health-USC Medical Group and senior medical director for Surgical Services at Prisma Health–Midlands. However, he said more experience and longer follow-up are necessary to confirm these promising mid-term results.

Nexus is a modular stent graft introduced via a 20 French delivery system with double flushing ports, which allows efficient de-airing. The main module is deployed over an axillofemoral guidewire to extend from the brachiocephalic trunk to the descending aorta and is combined with a pre-curved ascending module that conforms to the ascending aorta.

All patients had aneurysm size >55 mm and were considered high risk for conventional open arch surgery by a multidisciplinary team. Indications for treatment were aneurysm (15 [60%] patients) or dissection (10 [40%] patients), including seven patients previously treated surgically for type A dissection. Thirteen (52%) patients had prior thoracic aortic surgery. Supra-aortic bypasses were performed prior to Nexus implantation.

Technical success was achieved for all intended Nexus introductions and deployments (100%). At 30 days, two (8%) patients died from cardiac causes and two (8%) patients showed nondisabling stroke, which resolved completely within 30 days. During a mean follow-up of 25 months, there was one additional procedure-related mortality from stroke, and one patient was converted to open surgery following retrograde type A dissection. During follow-up, aneurysm size decreased or remained stable in 96% of the patients, with no aneurysm-related deaths.

The Nexus system is the first European CE mark–approved branched stent graft for the aortic arch. Design features that assist in minimizing manipulations may explain the high technical success, low rate of neurologic complications, and durability, allowing safe endovascular repair.

Find information on all the VIVA 2019 Late-breaking Clinical Trials


Related Content

News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
Subscribe Now